SOL SPA (IT:SOL)
:SOL
Want to see IT:SOL full AI Analyst Report?
SOL Stock Chart & Stats
€58.50
€0.65(1.72%)
At close: 4:00 PM EST
€58.50
€0.65(1.72%)
Day’s Range― - ―
52-Week Range€44.85 - €61.30
Previous CloseN/A
Volume101.19K
Average Volume (3M)31.19K
Market Cap
€5.44B
Enterprise Value€5.64B
Total Cash (Recent Filing)€364.71M
Total Debt (Recent Filing)€851.70M
Price to Earnings (P/E)32.7
Beta0.48
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)1.84
Shares Outstanding90,700,000
10 Day Avg. Volume35,913
30 Day Avg. Volume31,190
Financial Highlights & Ratios
PEG Ratio2.06
Price to Book (P/B)3.91
Price to Sales (P/S)2.50
P/FCF Ratio178.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€58.25Price Target Upside-0.43% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.08
Revenue Forecast (FY)€1.92B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained multi-year revenue growth indicates durable demand for the company’s products and incremental market penetration. Over 2–6 months this underpins stable top-line momentum, supports capacity utilization and planning, and reduces execution risk versus one-off cycles.
Stable Mid-Teens EBIT & Strong EBITDAReliable mid-teens EBIT and high-teens-to-mid-20s EBITDA margins reflect structural cost efficiency and pricing power in its chemical niches. These margins support reinvestment, debt servicing and resilience to input cost swings across multiple quarters.
Historically Reasonable Leverage & Healthy ROEA historically moderate debt profile paired with mid-teen ROE signals disciplined capital allocation and ability to generate attractive returns on invested capital. This balance-sheet track record supports future financing access and long-term strategic investments.
Bears Say
Weakened Free Cash FlowDeclining free cash flow reduces financial flexibility for dividends, buybacks, or debt reduction. Over the medium term this limits the company’s ability to self-fund growth or absorb shocks, increasing dependence on external financing if capex or working capital remain elevated.
Rising Leverage In 2025A notable increase in debt and debt-to-equity in 2025 raises refinancing and interest-rate vulnerability. If higher rates persist or earnings soften, elevated leverage could constrain strategic flexibility and increase the cost of capital over the coming quarters.
Gross Profit VolatilityMaterial swings in gross profit imply exposure to volatile input costs, pricing pass-through limits, or product-mix swings. This undermines earnings quality and forecasting reliability, complicating multi-quarter planning, margin protection and investor visibility into durable profitability.
SOL SPA News
SOL FAQ
What was SOL SPA’s price range in the past 12 months?
SOL SPA lowest stock price was €44.85 and its highest was €61.30 in the past 12 months.
What is SOL SPA’s market cap?
SOL SPA’s market cap is €5.44B.
When is SOL SPA’s upcoming earnings report date?
SOL SPA’s upcoming earnings report date is Sep 03, 2026 which is in 85 days.
How were SOL SPA’s earnings last quarter?
SOL SPA released its earnings results on Mar 26, 2026. The company reported €0.92 earnings per share for the quarter, beating the consensus estimate of N/A by €0.92.
Is SOL SPA overvalued?
According to Wall Street analysts SOL SPA’s price is currently Overvalued.
Does SOL SPA pay dividends?
SOL SPA pays a Annually dividend of €0.45 which represents an annual dividend yield of 0.8%. See more information on SOL SPA dividends here
What is SOL SPA’s EPS estimate?
SOL SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SOL SPA have?
SOL SPA has 90,700,000 shares outstanding.
What happened to SOL SPA’s price movement after its last earnings report?
SOL SPA reported an EPS of €0.92 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.04%.
Which hedge fund is a major shareholder of SOL SPA?
Currently, no hedge funds are holding shares in IT:SOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SOL SPA
SOL S.p.A., a global enterprise established in Monza, Italy, in 1927, operates as a subsidiary of Gas and Technologies World BV. The company primarily focuses on the research, manufacturing, and distribution of a diverse array of technical and medical gases, while simultaneously delivering comprehensive home healthcare solutions and associated medical equipment. Its extensive gas portfolio includes vital elements such as oxygen, nitrogen, and argon, alongside specialized gas mixtures, high-purity gases for the electronics industry, and food-grade gases. These products are supplied to various sectors including chemical, electronics, steel, metal, and food processing, as well as supporting environmental protection, scientific research, and healthcare. In the realm of home healthcare, SOL provides critical in-home therapies like oxygen, mechanical ventilation, and aerosol treatments. It also specializes in the diagnosis and management of respiratory sleep disorders, offers artificial nutrition programs, insulin pump therapy, immunotherapy, and dedicated support for pain and Parkinson's disease. Further extending its healthcare reach, the company delivers general home health and social care services, augmented by telemedicine platforms, digital health tools, and a range of healthcare aids. Beyond these core gas and home healthcare operations, SOL S.p.A. engages in a variety of complementary ventures. These encompass the design, construction, and management of biobanks; the generation and sale of hydroelectric power; and the provision of pre- and post-natal diagnostic screening. The company also develops and markets diagnostic systems and products for research and clinical applications across hospital, environmental, veterinary, and food sectors, alongside specialized bioshipping services for the secure transfer, storage, and handling of biological samples. Additional services include professional training, electromedical equipment support, hospital hygiene, environmental monitoring, and ambulance management, all facilitated by its proprietary InfoHealth SOLution web platform for operational oversight.
SOL Stock 12 Month Forecast
Average Price Target
€58.25
▼(-0.43% Downside)
Technical Analysis
Options Prices
Currently, No data available
---